舒血宁联合尼膜同治疗血管性痴呆32例临床研究  

Clinical Observation on the Treatment of Vascular Dementia Patients with the Combination of Shuxuening and Nimotop

作　　者：王雪如[1] 吴利银 

机构地区：[1]湖南农业大学医院内科,湖南长沙410128 [2]湖南省长沙县第二人民医院内科,湖南长沙410129

出　　处：《云南中医中药杂志》2009年第2期10-11,共2页Yunnan Journal of Traditional Chinese Medicine and Materia Medica

摘　　要：目的:观察舒血宁联合尼膜同治疗血管性痴呆的临床疗效。方法:将63例患者随机分为2组,治疗组32例,在一般治疗的基础上,联合应用舒血宁和尼膜同治疗,对照组31例,在一般性治疗的基础上,联合胞二磷胆碱和吡拉西坦治疗。分别在治疗前及治疗后第12周,对Folstein简易精神状态量表(MMSE)和长谷川痴呆量表(HDS)作为疗效评定指标进行评定,同时在治疗后对以MMSE得分为主要参考指标的疗效指数进行评定。结果:治疗组治疗前后MMSE、HDS评分比较差异有显著性(P<0.05)。治疗后第12周治疗组与对照组MMSE、HDS评分比较差异有显著性(P<0.05),疗效指数比较差异亦有显著性(P<0.05)。结论:舒血宁联合尼膜同治疗血管性痴呆有良好的疗效,且毒副作用小,安全性高,患者依从性好。Objective:To observe the clinical effect of Shuxuening and Nimotong on the treatment of vascular dementia patients.Methods:63 patients were randomly divided into a control group and a treatment group.32 patients in the treatment group were treated with Shuxuening and Nimotop while 31 patients in the control group were treated with citicoline and piracetam besides routine treatment.Folstein mini-mental state examination(MMSE) and Hasegawa Dementia Scale(HDS) as indicators were evaluated respectively before and after the treatment in the twelfth week,and at the same time MMSE score as the main reference was evaluated after the treatment.Results:The comparison of MMSE and HDS scores in the treatment group showed significance difference(P<0.0 5)before and after the treatment,but the comparison of MMSE and HDS scores in both groups showed significance difference(P<0.0 5)in the twelfth week.The clinical effect index also showed significance(P<0.0 5).Conclusion:The combination of Shuxuening and Nimotop has a good effect on the treatment of vascular dementia patients.

关 键 词：舒血宁 尼膜同 银杏叶提取物 血管性痴呆 

分 类 号：R749.13[医药卫生—神经病学与精神病学]